Reviva Research Development vs Operating Income Analysis

RVPHW Stock

USD 0.23 0.04 21.05%

Reviva Pharmaceuticals financial indicator trend analysis is much more than just breaking down Reviva Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Reviva Pharmaceuticals is a good investment. Please check the relationship between Reviva Pharmaceuticals Research Development and its Operating Income accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Research Development vs Operating Income

Research Development vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Reviva Pharmaceuticals Research Development account and Operating Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Reviva Pharmaceuticals' Research Development and Operating Income is -1.0. Overlapping area represents the amount of variation of Research Development that can explain the historical movement of Operating Income in the same time period over historical financial statements of Reviva Pharmaceuticals Holdings, assuming nothing else is changed. The correlation between historical values of Reviva Pharmaceuticals' Research Development and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Research Development of Reviva Pharmaceuticals Holdings are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Research Development i.e., Reviva Pharmaceuticals' Research Development and Operating Income go up and down completely randomly.

Correlation Coefficient

-1.0

Relationship Direction	Negative
Relationship Strength	Strong

View All Relationships

Research Development

Operating Income

Operating Income is the amount of profit realized from Reviva Pharmaceuticals operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Reviva Pharmaceuticals Holdings is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most indicators from Reviva Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Reviva Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Reviva Pharmaceuticals Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Enterprise Value is likely to climb to about 104.2 M in 2024, whereas Tax Provision is likely to drop 9,973 in 2024.

	2021	2023	2024 (projected)
Depreciation And Amortization	1.6M	223.9K	212.7K
Interest Income	182.8K	499.0K	523.9K

Depreciation And Amortization Interest Income

Reviva Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital
Total Assets		-0.47	0.03	0.26	0.95	0.9	-0.47	-0.99	-0.72	0.7	1.0	-0.96	-0.47	1.0	0.91	0.87	-0.47	-0.98	0.84	0.3	0.96	0.91	-0.47	1.0	-0.91	0.95
Short Long Term Debt Total	-0.47		0.45	-0.88	-0.32	-0.37	1.0	0.46	0.86	-0.54	-0.48	0.61	1.0	-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61	1.0	-0.47	0.52	-0.33
Other Current Liab	0.03	0.45		-0.53	0.17	-0.23	0.45	-0.02	0.54	-0.64	0.01	0.19	0.45	0.04	-0.29	-0.31	0.45	0.12	-0.25	-0.53	-0.05	-0.31	0.45	0.03	0.27	0.16
Total Current Liabilities	0.26	-0.88	-0.53		0.0	0.15	-0.88	-0.19	-0.82	0.55	0.27	-0.42	-0.88	0.21	0.28	0.56	-0.88	-0.3	0.57	1.0	0.09	0.33	-0.88	0.26	-0.24	0.01
Total Stockholder Equity	0.95	-0.32	0.17	0.0		0.86	-0.32	-0.98	-0.51	0.51	0.94	-0.88	-0.32	0.96	0.83	0.69	-0.32	-0.91	0.64	0.05	0.97	0.87	-0.32	0.95	-0.89	1.0
Property Plant And Equipment Net	0.9	-0.37	-0.23	0.15	0.86		-0.37	-0.91	-0.68	0.79	0.91	-0.88	-0.37	0.91	0.99	0.83	-0.37	-0.91	0.75	0.19	0.95	0.95	-0.37	0.9	-0.97	0.86
Current Deferred Revenue	-0.47	1.0	0.45	-0.88	-0.32	-0.37		0.46	0.86	-0.54	-0.48	0.61	1.0	-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61	1.0	-0.47	0.52	-0.33
Net Debt	-0.99	0.46	-0.02	-0.19	-0.98	-0.91	0.46		0.68	-0.67	-0.99	0.96	0.46	-0.99	-0.9	-0.82	0.46	0.98	-0.78	-0.23	-0.98	-0.93	0.46	-0.99	0.94	-0.98
Retained Earnings	-0.72	0.86	0.54	-0.82	-0.51	-0.68	0.86	0.68		-0.87	-0.73	0.84	0.86	-0.69	-0.76	-0.89	0.86	0.77	-0.86	-0.85	-0.62	-0.8	0.86	-0.72	0.74	-0.52
Accounts Payable	0.7	-0.54	-0.64	0.55	0.51	0.79	-0.54	-0.67	-0.87		0.71	-0.82	-0.54	0.69	0.83	0.92	-0.54	-0.8	0.88	0.58	0.67	0.79	-0.54	0.7	-0.77	0.53
Cash	1.0	-0.48	0.01	0.27	0.94	0.91	-0.48	-0.99	-0.73	0.71		-0.97	-0.48	1.0	0.92	0.88	-0.48	-0.98	0.85	0.31	0.96	0.92	-0.48	1.0	-0.92	0.95
Non Current Assets Total	-0.96	0.61	0.19	-0.42	-0.88	-0.88	0.61	0.96	0.84	-0.82	-0.97		0.61	-0.96	-0.9	-0.93	0.61	0.99	-0.9	-0.47	-0.91	-0.93	0.61	-0.96	0.92	-0.89
Non Currrent Assets Other	-0.47	1.0	0.45	-0.88	-0.32	-0.37	1.0	0.46	0.86	-0.54	-0.48	0.61		-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61	1.0	-0.47	0.52	-0.33
Cash And Short Term Investments	1.0	-0.43	0.04	0.21	0.96	0.91	-0.43	-0.99	-0.69	0.69	1.0	-0.96	-0.43		0.91	0.86	-0.43	-0.98	0.83	0.26	0.96	0.9	-0.43	1.0	-0.91	0.96
Common Stock Total Equity	0.91	-0.46	-0.29	0.28	0.83	0.99	-0.46	-0.9	-0.76	0.83	0.92	-0.9	-0.46	0.91		0.87	-0.46	-0.91	0.8	0.32	0.93	0.96	-0.46	0.91	-0.97	0.83
Common Stock Shares Outstanding	0.87	-0.57	-0.31	0.56	0.69	0.83	-0.57	-0.82	-0.89	0.92	0.88	-0.93	-0.57	0.86	0.87		-0.57	-0.92	0.99	0.6	0.77	0.83	-0.57	0.87	-0.8	0.7
Short Term Investments	-0.47	1.0	0.45	-0.88	-0.32	-0.37	1.0	0.46	0.86	-0.54	-0.48	0.61	1.0	-0.43	-0.46	-0.57		0.49	-0.54	-0.89	-0.39	-0.61	1.0	-0.47	0.52	-0.33
Non Current Liabilities Total	-0.98	0.49	0.12	-0.3	-0.91	-0.91	0.49	0.98	0.77	-0.8	-0.98	0.99	0.49	-0.98	-0.91	-0.92	0.49		-0.89	-0.35	-0.94	-0.92	0.49	-0.98	0.92	-0.92
Other Stockholder Equity	0.84	-0.54	-0.25	0.57	0.64	0.75	-0.54	-0.78	-0.86	0.88	0.85	-0.9	-0.54	0.83	0.8	0.99	-0.54	-0.89		0.61	0.7	0.75	-0.54	0.84	-0.72	0.65
Total Liab	0.3	-0.89	-0.53	1.0	0.05	0.19	-0.89	-0.23	-0.85	0.58	0.31	-0.47	-0.89	0.26	0.32	0.6	-0.89	-0.35	0.61		0.14	0.37	-0.89	0.3	-0.28	0.06
Net Invested Capital	0.96	-0.39	-0.05	0.09	0.97	0.95	-0.39	-0.98	-0.62	0.67	0.96	-0.91	-0.39	0.96	0.93	0.77	-0.39	-0.94	0.7	0.14		0.95	-0.39	0.96	-0.97	0.97
Property Plant And Equipment Gross	0.91	-0.61	-0.31	0.33	0.87	0.95	-0.61	-0.93	-0.8	0.79	0.92	-0.93	-0.61	0.9	0.96	0.83	-0.61	-0.92	0.75	0.37	0.95		-0.61	0.91	-0.99	0.87
Short Long Term Debt	-0.47	1.0	0.45	-0.88	-0.32	-0.37	1.0	0.46	0.86	-0.54	-0.48	0.61	1.0	-0.43	-0.46	-0.57	1.0	0.49	-0.54	-0.89	-0.39	-0.61		-0.47	0.52	-0.33
Total Current Assets	1.0	-0.47	0.03	0.26	0.95	0.9	-0.47	-0.99	-0.72	0.7	1.0	-0.96	-0.47	1.0	0.91	0.87	-0.47	-0.98	0.84	0.3	0.96	0.91	-0.47		-0.91	0.95
Capital Stock	-0.91	0.52	0.27	-0.24	-0.89	-0.97	0.52	0.94	0.74	-0.77	-0.92	0.92	0.52	-0.91	-0.97	-0.8	0.52	0.92	-0.72	-0.28	-0.97	-0.99	0.52	-0.91		-0.9
Net Working Capital	0.95	-0.33	0.16	0.01	1.0	0.86	-0.33	-0.98	-0.52	0.53	0.95	-0.89	-0.33	0.96	0.83	0.7	-0.33	-0.92	0.65	0.06	0.97	0.87	-0.33	0.95	-0.9

Click cells to compare fundamentals

Reviva Pharmaceuticals Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Reviva Research Development vs Operating Income Analysis

Research Development vs Operating Income

Research Development vs Operating Income Correlation Analysis

Correlation Coefficient

Research Development

Operating Income

Reviva Pharmaceuticals fundamental ratios Correlations

Reviva Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Reviva Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Current Deferred Revenue	+ 1.0	Short Long Term Debt Total
Non Currrent Assets Other	+ 1.0	Short Long Term Debt Total
Short Term Investments	+ 1.0	Short Long Term Debt Total

Capital Stock	- 0.99	Property Plant And Equipment Gross
Total Current Assets	- 0.99	Net Debt
Cash And Short Term Investments	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Debt	- 0.99	Total Assets
Total Current Assets	- 0.98	Non Current Liabilities Total